Latest Regulatory Approvals News

Brookside Energy has initiated drilling preparations for the Bruins Well in the prolific SWISH Play, aiming to boost production and increase its working interest to around 70%. This marks the first of three wells planned in its 2025 program, with strong production forecasts underpinning growth ambitions.

Beach Energy Limited has announced a fully franked ordinary dividend of AUD 0.03 per share for the half-year ending December 2024, payable on March 31, 2025.

News Corporation reported a robust second quarter for Fiscal 2025, with revenues climbing 5% to $2.24 billion and net income soaring 58%, while announcing the strategic sale of Foxtel to DAZN for A$3.4 billion.

AuKing Mining has entered a strategic agreement with Gage Capital Management, raising $300,000 through a 60 million share placement and selling two Tanzanian prospecting licences, positioning the company for growth across multiple jurisdictions.

BlueBet has announced a strategic acquisition of TopSport, supported by a $15 million equity raise, aiming to boost market share and deliver significant earnings accretion by FY26.

Brookfield Capital Partners has submitted a non-binding proposal to acquire Insignia Financial at A$4.60 per share, matching rival offers and setting the stage for a competitive bidding process.

Hartshead Resources has submitted a revised development report to the NSTA, unveiling a superior gas export route through CalEnergy's Saturn Banks pipeline that promises reduced costs and faster production.

Australian Rare Earths Limited (AR3) has obtained South Australian Government approval to expand its Overland Uranium Project, gaining rights over an additional ~1,000km² and greenlighting immediate drilling on high-potential targets.

Solstice Minerals has secured the advanced Nanadie Copper-Gold Project in Western Australia, acquiring a JORC-compliant Inferred Mineral Resource of 40.4Mt at 0.4% copper and 0.1g/t gold. The acquisition positions Solstice for growth amid strong long-term copper demand.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

A1 Investments & Resources Ltd reported a modest cash outflow for the December quarter while actively pursuing acquisition opportunities backed by secured funding. The company aims to finalize a deal soon, contingent on shareholder and regulatory approvals.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.